Authors reply: statins and new onset of diabetes: which one outweighs risk or benefit?

KEYWORDS:

• Diabetes
• statins
• cholesterol
• treatment

I read carefully the letter sent by the authors regarding my paper entitled ‘New onset diabetes mellitus induced by statins: current evidence’ and I would like to respond to the issues they are raising [1,2].

Abstract: In the abstract, it is correctly stated that among the possible causes of statin-induced NODM are decreased adiponectin levels and decreased insulin secretion, not increased insulin secretion as stated by the author.

Table 4: It is unfortunate that in the table it is wrongly stated ‘increased adiponectin levels.’ I take full responsibility for this oversight in correcting the proofs.

Section 4: Again in this section, it is wrongly stated ‘increased adiponectin levels’ although it correctly states ‘decreased ubiquinone levels.’ However, it should be realized that the subject of statin-induced NODM is very controversial and a large review and meta-analysis # 38 of all statins listed in this section states that statins increase adiponectin levels. Finally, I want to thank the author for his astute observations.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

This letter was not funded.